Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Infographic: Are data blind spots putting your launch at risk?

July 16, 2026 |  

Commercial pharma launches depend on confident, evidence-led decisions. Yet many launch teams are still working with fragmented data spread across multiple systems, making it difficult to understand market readiness, prioritize opportunities, and optimize commercial strategy.​

InConcert™ brings together omnichannel, field, clinical, and predictive insights in a single decision-making environment – helping commercial teams make smarter, faster decisions backed by Intelligent Commercialization™.

- PMLiVE

Discover how InConcert™ supports commercial launch planning​

If you’re looking for a quick, easy-to-understand overview of InConcert™, this one-page guide is the perfect place to start.​

In just a few minutes, you’ll discover:​

  • The commercial challenge the solution is designed to solve.​
  • How it enables intelligent launch planning.​
  • The four intelligence capabilities that power InConcert™.​
  • The value it delivers for commercial and launch teams.​
  • How it helps organizations make more informed launch decisions.​

Whether you’re exploring InConcert™ for the first time or introducing it to key stakeholders, this concise overview explains everything you need to know – all on a single page.

Download now. 

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Infographic: Conference Live

Conference Live gives you real-time insights, utilising the multimedia functionality of the smartphone in an innovative mobile app methodology. We conduct mobile conference research amongst physicians attending conferences, giving our clients…

Blog: The Cost of Counterfeits

The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.

Video: Self-pay and Emerging Markets

A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public…

News: Therapy Watch HCV expands into 4 additional EU markets

The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space…

News: Research Partnership launches new patient report – Living with Ulcerative Colitis

Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain…

Summer Intern experience at Research Partnership

We look for bright and inquisitive people who want to learn in a company that’s pushing the boundaries of pharmaceutical market research

Double win at Communiqué 2016: Pegasus scoops awards for Consultancy of the Year (for the second time!) and Excellence in Media Relations

Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the prestigious Consultancy of the Year award at the 2016 Communiqué Awards in London. The judges…

Beyond Andrology: Trends in Men’s Health in Emerging Markets

Published in eyeforpharma July 2016 by Rachel Howard

Pharma & life sciences division growth allows Pegasus to fill three new senior positions

Pegasus has expanded its pharma & life sciences senior team by appointing a new Associate Director and promoting two members of the existing team to Account Directors.

Infographic: HIV Market Snapshot

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single…